Hepatitis D Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major hepatitis D markets reached a value of US$ 665.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 845.3 Million by 2034, exhibiting a growth rate (CAGR) of 2.2% during 2024-2034.
The hepatitis D market has been comprehensively analyzed in IMARC's new report titled "Hepatitis D Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hepatitis D refers to a liver infection caused by the hepatitis D virus that only develops in individuals who have already been infected with the hepatitis B virus. The disease is mainly transmitted through contact with infected blood or bodily fluids. It can produce severe symptoms and significant illnesses, which can result in lifelong liver damage and possibly death. The most common indications associated with the condition include fatigue, jaundice, abdominal pain, loss of appetite, joint pain, dark urine, pale stools, etc. Some individuals with chronic hepatitis D may not experience noticeable symptoms for an extended period, but they can still be carriers of the virus and at risk of liver damage. The diagnosis of this ailment typically involves a combination of medical history assessment, physical examination, and laboratory tests, such as blood workups and specific serologic assays. In some cases, the medical practitioner may also perform numerous imaging studies, including ultrasounds, computed tomography (CT) scans, magnetic resonance imaging (MRI), etc., to evaluate the abnormalities in the liver or assess the extent of hepatic damage.
The increasing prevalence of hepatitis B infection that promote viral replication as well as the assembly of new virions is primarily driving the hepatitis D market. In addition to this, the rising incidences of injectable drug use and unprotected sexual intercourse, which can enhance the likelihood of virus transmission, are also bolstering the market growth. Furthermore, the widespread adoption of antiviral medications, including pegylated interferon-alpha and bulevirtide, for treating the ailment is acting as another significant growth-inducing factor. These agents mainly work by inhibiting the reverse transcriptase enzyme and suppressing viral DNA replication to reduce the risk of disease worsening and liver damage in patients. Additionally, the escalating demand for lifestyle changes, which involve consuming a healthy diet and avoiding alcohol, to relieve symptoms, improve hepatic function, and maintain overall health, is also creating a positive outlook for the market. Moreover, the emerging popularity of nucleoside analogs, owing to their numerous advantages, such as lowering viral load and decreasing liver inflammation, is expected to drive the hepatitis D market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the hepatitis D market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hepatitis D and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hepatitis D market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hepatitis D market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hepatitis D market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hepatitis D marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the hepatitis D market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hepatitis D market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hepatitis D market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of hepatitis D across the seven major markets?
What is the number of prevalent cases (2018-2034) of hepatitis D by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hepatitis D by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with hepatitis D across the seven major markets?
What is the size of the hepatitis D patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hepatitis D?
What will be the growth rate of patients across the seven major markets?
Hepatitis D: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hepatitis D drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hepatitis D market?
What are the key regulatory events related to the hepatitis D market?
What is the structure of clinical trial landscape by status related to the hepatitis D market?
What is the structure of clinical trial landscape by phase related to the hepatitis D market?
What is the structure of clinical trial landscape by route of administration related to the hepatitis D market?
The hepatitis D market has been comprehensively analyzed in IMARC's new report titled "Hepatitis D Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hepatitis D refers to a liver infection caused by the hepatitis D virus that only develops in individuals who have already been infected with the hepatitis B virus. The disease is mainly transmitted through contact with infected blood or bodily fluids. It can produce severe symptoms and significant illnesses, which can result in lifelong liver damage and possibly death. The most common indications associated with the condition include fatigue, jaundice, abdominal pain, loss of appetite, joint pain, dark urine, pale stools, etc. Some individuals with chronic hepatitis D may not experience noticeable symptoms for an extended period, but they can still be carriers of the virus and at risk of liver damage. The diagnosis of this ailment typically involves a combination of medical history assessment, physical examination, and laboratory tests, such as blood workups and specific serologic assays. In some cases, the medical practitioner may also perform numerous imaging studies, including ultrasounds, computed tomography (CT) scans, magnetic resonance imaging (MRI), etc., to evaluate the abnormalities in the liver or assess the extent of hepatic damage.
The increasing prevalence of hepatitis B infection that promote viral replication as well as the assembly of new virions is primarily driving the hepatitis D market. In addition to this, the rising incidences of injectable drug use and unprotected sexual intercourse, which can enhance the likelihood of virus transmission, are also bolstering the market growth. Furthermore, the widespread adoption of antiviral medications, including pegylated interferon-alpha and bulevirtide, for treating the ailment is acting as another significant growth-inducing factor. These agents mainly work by inhibiting the reverse transcriptase enzyme and suppressing viral DNA replication to reduce the risk of disease worsening and liver damage in patients. Additionally, the escalating demand for lifestyle changes, which involve consuming a healthy diet and avoiding alcohol, to relieve symptoms, improve hepatic function, and maintain overall health, is also creating a positive outlook for the market. Moreover, the emerging popularity of nucleoside analogs, owing to their numerous advantages, such as lowering viral load and decreasing liver inflammation, is expected to drive the hepatitis D market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the hepatitis D market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hepatitis D and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hepatitis D market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hepatitis D market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hepatitis D market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hepatitis D marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the hepatitis D market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hepatitis D market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hepatitis D market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of hepatitis D across the seven major markets?
What is the number of prevalent cases (2018-2034) of hepatitis D by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hepatitis D by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with hepatitis D across the seven major markets?
What is the size of the hepatitis D patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hepatitis D?
What will be the growth rate of patients across the seven major markets?
Hepatitis D: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hepatitis D drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hepatitis D market?
What are the key regulatory events related to the hepatitis D market?
What is the structure of clinical trial landscape by status related to the hepatitis D market?
What is the structure of clinical trial landscape by phase related to the hepatitis D market?
What is the structure of clinical trial landscape by route of administration related to the hepatitis D market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HEPATITIS D - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HEPATITIS D - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HEPATITIS D - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 HEPATITIS D - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HEPATITIS D - UNMET NEEDS
10 HEPATITIS D - KEY ENDPOINTS OF TREATMENT
11 HEPATITIS D - MARKETED PRODUCTS
11.1 List of Hepatitis D Marketed Drugs Across the Top 7 Markets
11.1.1 Hepcludex (Bulevirtide) - MYR Pharma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HEPATITIS D - PIPELINE DRUGS
12.1 List of Hepatitis D Pipeline Drugs Across the Top 7 Markets
12.1.1 VIR-3434+VIR-2218 - Vir Biotechnology
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 JNJ73763989 - Janssen Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Peginterferon lambda 1a - Eiger BioPharmaceuticals/ZymoGenetics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Lonafarnib - Eiger Biopharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 P1101 - AOP Orphan Pharmaceuticals/PharmaEssentia Corporation
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HEPATITIS D - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HEPATITIS D – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HEPATITIS D - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hepatitis D - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hepatitis D - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hepatitis D - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hepatitis D - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hepatitis D - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hepatitis D - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hepatitis D - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hepatitis D - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hepatitis D - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hepatitis D - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hepatitis D - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hepatitis D - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hepatitis D - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hepatitis D - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hepatitis D - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hepatitis D - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hepatitis D - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hepatitis D - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hepatitis D - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hepatitis D - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hepatitis D - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hepatitis D - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hepatitis D - Access and Reimbursement Overview
16 HEPATITIS D - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HEPATITIS D MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HEPATITIS D MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HEPATITIS D - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HEPATITIS D - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HEPATITIS D - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 HEPATITIS D - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HEPATITIS D - UNMET NEEDS
10 HEPATITIS D - KEY ENDPOINTS OF TREATMENT
11 HEPATITIS D - MARKETED PRODUCTS
11.1 List of Hepatitis D Marketed Drugs Across the Top 7 Markets
11.1.1 Hepcludex (Bulevirtide) - MYR Pharma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HEPATITIS D - PIPELINE DRUGS
12.1 List of Hepatitis D Pipeline Drugs Across the Top 7 Markets
12.1.1 VIR-3434+VIR-2218 - Vir Biotechnology
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 JNJ73763989 - Janssen Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Peginterferon lambda 1a - Eiger BioPharmaceuticals/ZymoGenetics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Lonafarnib - Eiger Biopharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 P1101 - AOP Orphan Pharmaceuticals/PharmaEssentia Corporation
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HEPATITIS D - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HEPATITIS D – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HEPATITIS D - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hepatitis D - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hepatitis D - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hepatitis D - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hepatitis D - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hepatitis D - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hepatitis D - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hepatitis D - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hepatitis D - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hepatitis D - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hepatitis D - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hepatitis D - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hepatitis D - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hepatitis D - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hepatitis D - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hepatitis D - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hepatitis D - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hepatitis D - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hepatitis D - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hepatitis D - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hepatitis D - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hepatitis D - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hepatitis D - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hepatitis D - Access and Reimbursement Overview
16 HEPATITIS D - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HEPATITIS D MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HEPATITIS D MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
